Merck Phase 2b Trial Reports MASH Resolution Rates of 56%–63%

Merck said its Phase 2b trial met its primary endpoint. MASH resolution without worsening fibrosis at 52 weeks was 56%, 63% and 61% across efinopegdutide doses, versus 13% for placebo. Fibrosis improvement rates were 43%, 52% and 34%, versus 21% for placebo.